Dechra Pharmaceuticals PLC

Dechra Pharmaceuticals PLC

Annual Report and Accounts for the year ended 30 June 2012

5. Non-underlying Items

Non-underlying items comprise:

2012
£'000
2011
£'000
Amortisation of intangible assets acquired as a result of acquisitions10,8718,938
Rationalisation costs2,525474
Expenses of the acquisition of DermaPet Inc.585
Expenses of the acquisition of Genitrix Limited108
Expenses of the acquisition of Eurovet Animal Health B.V.2,315
15,71110,105

Rationalisation costs in 2012 relate to the integration of Eurovet Animal Health B.V. This consists primarily of the costs incurred in relation to the rationalisation of the four duplicated sales offices and associated sales teams.

Rationalisation costs in 2011 relate to the integration of DermaPet Inc. and Genitrix Limited.

We use cookies and track users anonymously, check this box and save to disable. We are inferring consent by continuing.